The UK’s biosolutions sector has quietly established itself as a billion‑pound frontier industry, with companies raising £1.46 billion in equity investment since 2018, according to new analysis from BIA BioSolutions.
The figure highlights both the scale and maturity of a sector built on the UK’s strengths in engineering biology, and its growing role in addressing one of today’s most pressing economic challenges: how to insulate national supply chains from global shocks.
Biosolutions – technologies that use biological processes to replace or transform fossil‑based and resource‑intensive systems – span agriculture, chemicals, materials and fuels.
By enabling more domestic, bio‑based production, proponents argue the sector represents not just a climate solution, but a strategic economic asset.
Insulating the economy from global volatility
Drawing on in‑house analysis of 155 innovative UK biosolutions companies, BIA’s new report argues that biology‑based production can help reduce the UK’s reliance on imported, often volatile inputs.
From microbial crop inputs and biofertilisers to fermentation‑based chemicals and materials, biosolutions offer alternatives to supply chains exposed to geopolitical tension, trade disruption and price volatility.
“By replacing fossil‑based, import‑dependent supply chains with domestic, biology‑based production, biosolutions are a critical security asset,” the report notes, positioning the sector as a layer of economic resilience rather than a niche sustainability play.
This framing appears to be resonating with investors. Since 2018, biosolutions companies have attracted capital at a scale that places them alongside other UK frontier technologies, reflecting growing market pull from industries seeking secure, low‑carbon and locally anchored inputs.
International capital flows into UK biology
The analysis also underlines the UK’s global appeal as a destination for biosolutions investment.
Between 2018 and 2025, more than 60.6% of investors in UK biosolutions companies were based overseas, with the US and Europe accounting for the majority. BIA describes this as a clear vote of confidence in the UK’s scientific excellence, entrepreneurial quality and long‑term potential.
That international backing has helped sustain company formation and scale‑up over several years, particularly during the sharp acceleration in investment activity seen up to 2022.
Momentum paused, not broken
While the long‑term trend points to strong growth, the data also captures a clear slowdown after 2022. Annual investment dipped in 2023 and 2024 before recovering to £259 million in 2025, mirroring broader macroeconomic tightening rather than any sector‑specific weakness.
Crucially, BIA notes that deal activity has remained consistent, with continued later‑stage investment and rising international participation.
For the trade body, this suggests significant innovation and company growth is waiting to be unlocked as global capital markets stabilise and risk appetite returns.
Regulation remains a structural challenge
Despite the positive investment story, regulation continues to weigh heavily on the sector – particularly for early‑stage companies.
UK biosolutions companies frequently cite mis‑fit regulatory frameworks, slow approval processes, high compliance costs and uncertainty as major constraints on growth.
Many biological products are assessed under regimes originally designed for synthetic chemicals, creating disproportionate burdens for living, low‑toxicity technologies.
This challenge falls hardest on innovative SMEs, which often lack the resources to absorb prolonged regulatory timelines. For many founders, regulation – rather than science or engineering – has become the dominant barrier to commercialisation.
Scaling biology needs more than capital
As the sector enters its next phase, BIA argues that future growth will depend on three enabling factors: regulatory reform, patient scale‑up capital and accessible infrastructure.
Public funding, particularly through Innovate UK, continues to play an important role in de‑risking early research and feeding the pipeline that later‑stage investors rely on. But BIA warns that without clear pathways to scale, the UK risks seeing promising companies commercialise overseas.
“With £1.46 billion flowing into the biosolutions ecosystem, it is clear that the sector remains a resilient priority for investment,” said Linda Bedenik, head of biosolutions and international policy at BIA.
“However, to fully realise this potential and navigate the current investment climate, we must bridge the gap between breakthrough science and market‑ready products.”
Biology and strategic autonomy
For Jane Wall, managing director at BIA, biosolutions lie at the convergence of climate, competitiveness and national resilience.
“As global supply chains face increasing pressure and resource volatility, biotechnology is becoming central to strengthening our strategic autonomy and ability to diversify,” she said.
By driving demand for bio‑based products and fostering regional and international collaboration, Wall argues the UK can reduce exposure to unstable global markets while positioning itself as a leader in what BIA describes as the coming “biorevolution”.
“We are a global leader in engineering biology,” she added. “But scientific breakthroughs alone are not enough. They require a dedicated space for innovation to meet scale and ideas to meet markets.”
Turning paused momentum into the next growth wave
BIA believes the fundamentals are firmly in place for the UK biosolutions sector to re‑accelerate, provided policy and regulatory frameworks evolve in step with innovation.
With rising interest in resource security, domestic production and low‑carbon alternatives, biosolutions are increasingly being seen not just as a sustainability lever, but as a core component of a resilient UK economy.
With the right conditions, it is hoped today’s pause in investment momentum could yet give way to the next wave of industrial growth.
Read the full BIA BioSolutions report here: https://biosolutions.org.uk/resource/introducing-bia-biosolutions.html
